Itacitinib

DB12154InvestigationalSmall molecule

Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.

Mechanism: Pharmacologically active on Tyrosine-protein kinase JAK1
Curator reviewed
Formula / weight: C₂₆H₂₃F₄N₉O · 553.526 g/mol (avg)
Code names: INCB-039110

Resolves to

Compound

UNII19J3781LPMCAS1334298-90-6ChEMBLCHEMBL3622820PubChem53380437

Clinical / RWD

ATCL04AF05

Structure

InChIKeyKTBSXLIQKWEBRB-UHFFFAOYSA-NSMILESFC1=C(N=CC=C1C(=O)N1CCC(CC1)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1)C(F)(F)F

Targets

P23458JAK1O60674JAK2

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

50Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 7 drug categories

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Itacitinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In